MedTrace Logo

Natural History Study in Pediatric Patients With MYBPC3 Mutation-associated Cardiomyopathy

NCT05112237 · Status: RECRUITING · Type: OBSERVATIONAL · Enrollment: 200

Last updated 2024-11-13

No results posted yet for this study

Summary

The objective of this study is to collect information on patients with cardiomyopathy (CM) due to mutations in the MYBPC3 gene, to evaluate their disease course, burden of illness, risk factors for this disease, and the quality of life (QoL). This study will also collect information on treatments, procedures and outcome in infants and children up to 18 yrs who have this mutation.

Conditions

Sponsors & Collaborators

  • Tenaya Therapeutics

    lead INDUSTRY

Eligibility

Min Age
0 Years
Max Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2021-11-01
Primary Completion
2028-06-30
Completion
2028-06-30

Countries

  • United States
  • Canada
  • Spain
  • United Kingdom

Study Locations

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT05112237 on ClinicalTrials.gov